FLITTE THE APPENDIX A

Sequence	(G)DFLAEGGGVR(G)	(G)DFLAEGGGVR(G)	(G)DFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(E)GDFLAEGGGVR(G)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(K)	(H)RIHWESASLL(R)	(H)RIHWESASLL(K)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)
Protein Name	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Apolipoprotein	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
MW	1020	1020	1020	1077	1077	1077	1077	1077	1097	1097	1097	1097	1097	1097	1206	1206	1206	1206	1206	1206	1206	1206	1206	1206	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211
Disease	MI	M	MI	M	M	Mi	M	M	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Renal Failure	Renal Failure	Renal Failure	Renal Failure	Renal Failure	Renal Failure	Renal Failure	Renal failure	Renal failure	Renal failure	M	M	M	M	M	×	M	IW	M	×	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH
Patient History	MI Hy of arthritis	ואוי דוא סו מותוומסי			IW	Acute MI SK???	NTH XH IM AVEW O-DON		Rectal bleed Asthma, NIDDM	MI NIDIM	A fib Diahates smoker HTN		A fib. Diabetes, smoker, HTN					A STATE OF THE STA		A DESTRUCTION OF THE PROPERTY	The state of the s	Unstable andina hemodialvsis	Thetable andina hemosdialvsis	Olisiabio ariginal Prior Hy CAN hemodalysis	Napid autor 15, 1151 15, 0, 11 15, 15, 15, 15, 15, 15, 15, 15, 15,	GE (gastroesophageal) reflux	Inferior MI, Hiatal Hernia	MI, NIDDM							Acute CVA Basal dandia	HTM previous CVA CVA (R MCA) used tPA	CVA transfer to VA	LIAN ICH	Drior CVA South CVA (LMCA)	HTN acute CVA (R subcortical	HTN, Diabetes, acute CVA (R parietal)
ΔΩΦ	280	3		77	- 20	22	2 7 7	3	67	1/2	63	72	£ 6	1	82	20	10	. 0	00	3 6	20 20	3 %	3 8	3 8	3 5	65	200	92	2 80	52	65	3			ž	2 2	17	1 0	2 2	7.0	2,
Gender	200100	Σ		ш	- 2	2 2	2	i.	Ц	_	L 2	2	2 2	ž į	Σ	Ē	ם	L 2	≥ 2	≥ ⊔	L. L	_ 2	2 2	<u>≥</u> ⊔	_ u	- ≥	Щ	-	. ≥	2	Σ				Ц	- 2	2 2	Σ	≥ ≥	2	Į.
# 9000	1.	SUCCINION OF	HN3-3320	SCINCTION OF	S CON 00	S S S S S S S S S S S S S S S S S S S	S NOOL O	20000	HNS-5328	CO NO. 76	SU CON US	104 000	TWH 039	184 088	S I CON 01	SONO CO	00 NOO 100	90 NOO 10	SJ CON 08	SUCCINO SOLVE	82 CON 10	SOON 14	00 CON 04	02 CON 12	SI CON 13	SON OO	S CON 3	SI CON 18	SI CON 17	S. CON 19	S CON 2	UNIO C 199	LINIC C 128	LING-032	11NO-0000	21-12	2 5	8-00	05-50	CO-53	CU-38

Sequence	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(A) I IOVUMINITIONAL																			
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f											
MM	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1211	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348	1348
Disease	CHF	CHF	CHE	CHF	出	농	뚱	분	光	뚱	CH.	CHF	胀	CHF	CHF	CHF	CHF	胀	CHE	出	吊	M	MI	MI	M	M	MI	M	M	M	Œ	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH
Patient History	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3			Hemodialysis	hemodialysis					and the second s		ICH, secondary to AVM	ICH	Acute CVA, Basal ganglia	HTN, ICH right thalmic	HTN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA		Prior CVA, acute CVA (L MCA)	HTN, acute CVA (R subcortical_	HTN Dishetes acute CVA (Binarietal)						
Age	61	65	29	75	77	92	29	29	79	09	43	45	29	99	51	64	59	9/	51	62	70	77	65	50	65	58	52	65				69	44	54	99	72	47	26	72	72	67
Gender	Σ	ഥ	u.	ш	ᄔ	ட	Σ	Σ	Σ	Σ	Σ	М	M	ı	Σ	M	Σ	Ł	Σ	Σ	Σ	ட	Σ	T.	ı	Σ	Σ	Σ			_	11.	ц	ш	Σ	Σ	Σ	Σ	Σ	Σ	ш
Code #	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	69-NO	CU-12	CU-15	CU-10	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38

# 0000	Gender	Δηρ	Patient History	Disease	≥ ⊠	Protein Name	Sequence
		2	HTN Prior CVA ICH (B thalamic hemorrhade)	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
00-00	ΞΞ	40	HTN. Prior CVA. CVA	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
CU-00	2 2	43	HTN. Prior CVA, ICH	Stroke-ICH	1348	Complement C3f	(T)HRIHWESASLL(R)
23604 - KKB	Σ	61	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23707 - KL	щ	65	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASIL(R)
22703 - MMS	ш.	67	STAGE 3	CH	1348	Complement C3f	(T)HRIHWESASLL(R)
20206 - MM		75	STAGE 4	HS	1348	Complement C3f	(T)HRIHWESASLL(R)
22103 - GM	. и.	77	STAGE 3	SFF	1348	Complement C3f	(T)HRIHWESASLL(R)
21813 - GR	. ப	92	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23008 - GFB	2	67	STAGE3 - DEAD	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23402 - HM	Σ	67	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20208 - HIF	Σ	79	STAGE 3	出	1348	Complement C3f	(T)HRIHWESASLL(R)
22803 - HB	Σ	09	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23616 - JGK	Σ	43	STAGE 3	SH	1348	Complement C3f	(T)HRIHWESASLL(R)
20803 - FW	Σ	45	Acute MI - STAGE 3	长	1348	Complement C3f	(T)HRIHWESASLL(R)
23421 - FB	Σ	59	STAGE 3	送	1348	Complement C3f	(T)HRIHWESASLL(R)
22813 - CL	ш	99	STAGE 4	CH	1348	Complement C3f	(T)HRIHWESASLL(R)
23130 - ER	Σ	51	STAGE 3	光	1348	Complement C3f	(T)HRIHWESASLL(R)
23105 - FC	Σ	64	STAGE 3	出	1348	Complement C3f	(T)HRIHWESASLL(R)
23116 - FC	Σ	29	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
20414 - EYG	ட	9/	STAGE 3	CFF	1348	Complement C3f	(1)HRIHWESASLL(K)
23130 - ER	Σ	51	STAGE 3	CHF	1348	Complement C3f	(T)HRIHWESASLL(R)
23134 - FC	Σ	62	STAGE 3	붕	1348	Complement C3f	(T)HKIHWESASLL(K)
20102 - EAB	Σ	70	STAGE 3	상	1348	Complement C3f	(I)HKIHWESASLL(K)
SJ CON 01	Σ	82		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 05	ட	29		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 06	ഥ	77		ΞW.	1350	Alpha Florinogen	
SJ CON 06	ட	77		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 09	Σ	8		Kenal Fallure	025	Alpria Fibiliogell	(D)SECON (D)
SJ CON 07	Σ	92		III I	1350	Alpha Fibringgen	(D)SESDILAEGGGVI(G)
SJ CON 07	Σ	9		Kenal railure	020	Alpha Fibrilogen	(D)SECON EVENOUS (C)
SJ CON 10	ш	20	ALV.	: Wi	1350	Alpha Flbrinogen	(D)SESDITATEGOOVI(G)
SJ CON 10	ட	ည		Renal Failure	1350	Alpha Fibrinogen	(D)SESDILATEGEGGVN(G)
SJ CON 14	LL.	92	5 (40)	MI	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 14	ட	92		Renal Failure	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 17	Σ	28		M	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 19	Σ	25		Z	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
SJ CON 21	Σ	92		M	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ22				M	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
HNS-SJ28				M	1350	Alpha Fibrinogen	(D)SESDFLAEGGGVR(G)
UNIO 0 133			Construction of the constr	Z	1350	Alpha Fibrinoden	(D)SESDFLAEGGGVR(G)

Sequence	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHKFK(U)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHKFK(U)	(R)DAHKSEVAHRFK(D)	(R)DAHKSEVAHKFK(D)	(R)DAHKSEVAHKFK(D)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(K)										
Protein Name	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Serum Albumin	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f																			
MW	1350	1350	1350	1406	1406	1406	1406	1406	1406	1406	1406	1406	1406	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449
Disease	Renal failure	Renal failure	Renal failure	CHE	CHE	胀	岩	분	CHE	CHF	CHF	CHF	CHF	M	M	M	M	MI	M	Σ	M	Ψ	M	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	CAF	CHF
Patient History	Unstable andina hemodialvsis	Unstable anging, hemosdialysis	Rapid atrial Fib. Prior Hx CAN hemodialysis	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3				(Analysis)							ICH. secondary to AVM	CH	Acute CVA, Basal ganglia	HTN, ICH right thalmic	HTN, acute CVA	HTN, ICH (cerebellar vermis)	HTN, previous CVA, CVA (R MCA) used tPA		HTN, ICH	HTN, ICH	Prior CVA, acute CVA (L MCA)		HTN Diabetes, acute CVA (R parietal)	HTN Prior CVA, ICH (R thalamic hemorrhage)	HTN. Prior CVA. CVA	HTN, Prior CVA, ICH	STAGE 3	STAGE 3						
Δηρ		88	80	45	29	99	52	64	29	76	51	62	20	77	65	20	955	22	52	55	3			69	44	54	99	20	76	72	47	55	56	72	72	67	6	49	43	61	92
Gondar	2000	2	Ē	. ≥	≥	ш	. 2	Σ	2	L	. 2	Σ	Σ	Ŀ	Σ	ц	. և	. 2	2	2	•			Ц	. 4	ш	Σ	Σ	ш	Σ	Σ	Σ	Σ	Σ	≥	ш	. ≥	Σ	Σ	Σ	ш
# 0000	5	S CON 04	S CON 13	20803 - FW	23421 - FB	22813 - CI	23130 - FR	23105 - EC	23116 - FC	20414 - FYG	23130 - ER	23134 - FC	20102 - EAB	S.I CON 06	S.I CON 07	S.I CON 10	S I CON 14	SI CON 17	S CON 19	S I CON 21	HNIS. S 122	HNS-5.128	HNIS-5 133	00-0117	CU-12	CU-15	CU-10	CU-14	CU-16	CU-18	CU-19	CU-28	CU-30	CI 1-33	CH-37	C11-38	09-112	01-66	CU-75	23604 - KKB	23707 - KL

REPUBLICATION OF THE PROPERTY OF THE STATE O

_	Gender	<u> </u>	Pa	Disease	MM	Protein Name	Sequence
22703 - MMS	ഥ	29	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
20206 - MM	ட	75	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22103 - GM	ட	77	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
21813 - GR	LL	65	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23008 - GFB	Σ	29	STAGE3 - DEAD	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23402 - HM	Σ	29	STAGE 3	SF	1449	Complement C3f	(I)THRIHWESASLL(R)
20208 - HIF	Σ	79	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
22803 - HB	Σ	90	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23616 - JGK	Σ	43	STAGE 3	光	1449	Complement C3f	(I)THRIHWESASLL(R)
20803 - EW	Σ	45	Acute MI - STAGE 3	Ю	1449	Complement C3f	(I)THRIHWESASLL(R)
23421 - FB	Σ	59	STAGE 3	岩	1449	Complement C3f	(I)THRIHWESASLL(R)
22813 - CL	ட	99	STAGE 4	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	Σ	51	STAGE 3	똤	1449	Complement C3f	(I)THRIHWESASLL(R)
23105 - FC	Σ	64	STAGE 3	光	1449	Complement C3f	(I)THRIHWESASLL(R)
23116 - FC	Σ	59	STAGE 3	뚱	1449	Complement C3f	(I)THRIHWESASLL(R)
20414 - EYG	щ	92	STAGE 3	托	1449	Complement C3f	(I)THRIHWESASLL(R)
23130 - ER	Σ	51	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
23134 - FC	Σ	62		长	1449	Complement C3f	(I)THRIHWESASLL(R)
20102 - EAB	Σ	70	STAGE 3	CHF	1449	Complement C3f	(I)THRIHWESASLL(R)
SJ CON 01	Σ	82	A A ST A CALLED TO THE STATE OF	Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 05	ட	29		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 06	ட	77	and the second s	Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 09	≥	80		Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	Σ	65	And the second s	Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 10	u.	20	Communication of the control of the	Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 14	ய	65	THE PERSON NAMED IN COLUMN TO A SECOND NAMED IN COLUMN TO	Renal Failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 04	Σ	99	Unstable angina, hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
N 1	Σ	89	Unstable angina, hemosdialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 13	L	8	Rapid atrial Fib, Prior Hx CAN hemodialysis	Renal failure	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-12	ц.	44	ICH	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-10	≥	99	HTN, ICH right thalmic	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-16	ட	9/	HTN, ICH (cerebellar vermis)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-37	Σ	72	HTN, acute CVA (R subcortical	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
CU-38	ш	29	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	1465	Alpha Fibrinogen	(A)DSGEGDFLAEGGGVR(G)
SJ CON 07	Σ	65	Table of the state	W	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 10	11.	20	The state of the s	Mi	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
HNS-SJ22				MI	1518	Alpha Fibrinogen	(T)ADSGEGDFLAEGGGVR(G)
SJ CON 01	Σ	82	The state of the s	Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 05	ш	29		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 06	L	77	The state of the s	Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)
SJ CON 09	Σ	8		Renal Failure	1521	Serum Albumin	(R)DAHKSEVAHRFKD(L)

Sequence	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(D)PNHFRPAGLPEKY(-)	(D)PNHFRPAGLPEKY(-)	(D)PNHFRPAGLPEKY(-)	(T)ADSGEGDFLAEGGGVR(G)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(K)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	(K)ITHRIHWESASLL(R)	
Protein Name	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin	Serum Amyloid A	Serum Amyloid A	Serum Amyloid A	Alpha Fibrinogen	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
MW	1521	1521	1521	1521	1521	1521	1525	1525	1525	1536	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1562	1616
Disease	Renal Failure	Renal Failure	Renal Failure	Renal failure	Renal failure	Renal failure	Z	V	W	M	W	IW	M	N	W	M	W	MI	M	FFC	去	HS.	분	CHF	CHF	분	CHF	CHF	CHF	CHF	분	CHF	CHF	出	去	붕	岩	岩	분	CHF	M
Patient History				late organical demoderation	Unstable andina hemosdialysis	Danid atrial Eth Drior Hx CAN hemodialvsis	Napid attlat 115, 1 101 115 Oras totalogical	5.00		distribution of the state of th		the state of the s		List of the state		The state of the s				STAGE 3		STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STOCE 3	STAGE 3	STAGE 3	
000		000	200	00	000	000	0 2	3			7.7	, ,	လ င်	2	8	3 5	70	3		6	2 6	27	3 4	22	. G	67	67	79	9	43	45	200	99	2,7	64	2 02	76	2 7	6	2 2	12
Condor	20100	≥L	L L	_ 2	2	<u> </u>	L	_			L	ا	∑ L	L	∟ 2	≥ 2	≥ 2	Σ		74	<u>≥</u> L	L	1	_ u	. ц	- 2	Σ	Σ	. ≥	2	Σ	2	ш	. 2	≥	2	<u> </u>	_ 2	2	Σ	
# 0000	٦,	SUCON OF	SJ CON 10	SJ CON 14	SUCON 04	00 CON -	SUCON IS	01 NO 10	HNS-8322	0702-201H	HNS-SJ22	SJ CON 06	SJ CON 07	SJ CON 10	82 CON 14	20 CON 12	SJ CON 19	S NOON S	HING-OLIZA	HNG-0003	23004 - NND	23/0/ - NL	227 US - IVINIS	20200 - MINI	24843 GP	23008 - GFR	23402 - HM	20102 20208 - HIF	22202 IIII	22,000 23616 - IGK	20803 - FW	23/24 - FR	22813 - CI	23130 - ER	23100 - LIN	23103-10	23110-110	20414 - ETG	23130 - ER	20102 - EAB	SJ CON 06

FILTER THE STATE OF THE STATE O

Sequence										(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(K)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(K)	(S)KITHKIHWESASLL(K)	(S)KITHKIHWESASLL(R)	(S)KITHKIHWESASLL(K)	(S)KIIHKIHWESASLL(K)	(S)KII TRITAVESASEL(A)		(S)KII HKIHWESASLL(K)	(S)KITHRIHWESASLL(K)	(S)KITHRIHWESASLL(K)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(K)	(S)KITHRIHWESASLL(K)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(K)
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C31	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f									
MM	1616	1616	1616	1616	1616	1616	1616	1616	1616	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690	1690
Disease	Mi	Σ	M	Mi	M	M	M	M	M	M	M	M	M	M	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	몽	CHF	CHF	CHF	CHF	SH	出	出	CFF	CHF	CHE
Datient History	t agolf thoras													5.5	ICH, secondary to AVM	HO	Acute CVA. Basal ganglia		HTN. acute CVA	HTN. ICH (cerebellar vermis)	HTN. previous CVA, CVA (R MCA) used tPA		HTN. ICH	HTN, ICH	Prior CVA, acute CVA (L MCA)	HTN, acute CVA (R subcortical_	HTN, Diabetes, acute CVA (R parietal)	HTN, Prior CVA, ICH (R thalamic hemorrhage)	HTN, Prior CVA, CVA	HTN, Prior CVA, ICH	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3
000	200	S C	65	28	52	65	3			77	65	200	65	28	69	44	45	99	200	92	72	47	22	26	72	72	29	64	49	43	61	65	29	75	77	65	29	29	79	09	43
1000	iani ian	Σ μ	_ 11	. 2	Σ	Σ				L	- ≥	L	. 4	Σ	LL.	<u>_</u>	. 14	. 2	2	L	. 2	Σ	≥	Σ	Σ	Σ	Ь	Σ	Σ	Σ	Σ	止	ш.	ш	L	Ŀ	≥	Σ	≥	Σ	Σ
	٦.	SUCON OF	SON 10	S.I CON 17	8.1 CON 19	S.I CON 21	HNS-8.122	HNS-S.128	HNS-S,133	S.I.C.O.N.O.G.	S.I CON 07	S. I.CON 10	S.I CON 14	S.I CON 17	CU-69	C1112	C11.15	CII-10	C1-14	C11-16	CI-18	CI-19	CI 1-28	CI 1-30	CU-33	CU-37	CU-38	09-NO	CU-66	CU-75	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - IGK

FILE THE APPENDIX A

Sequence	(S)KITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)									
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f										
MW	1690	1690	1690	1690	1690	1690	1690	1690	1690	1600	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	17771	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777
Disease		光	长	长			岩	H.S.	분	370	Tyno II Diabatas	Type II Diahafas	Type II Diabetes	Type II Diahetes	M	Tyno II Diahatas	Tyne II Diahetes	Tyne II Diahetes	M	N N	W		Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	OHE STATE	CHF	CHF
Patient History	Acute MI - STAGE 3		STORE 4	STAGE 3	STAGE 3	0170E 0	O TOCHO	0170F3	01AGE 3	0.10010	SIAGE 3	NIDDIM, CHF, Hypothalenia??	ان	Hernodialysis	Herridularysis	MINDRA LITAL DIOCOS Angino	אוטטואן, חווא, אוטריוא	Anhaoia Dt haminaralveie	Apriasia, Ni Italiipaiaiysis,				MVA of yachacoco UOI		Acute CVA. Basal ganglia	HTN. ICH right thalmic	HTN. acute CVA	HTN ICH (cerebellar vermis)	HTM previous CVA CVA (R MCA) used tPA	CVA. transfer to VA	HIN. ICH	HIN. ICH	Prior CVA, acute CVA (L MCA)		HTN Diabetes acute CVA (Riparietal)	HTN Brior CVA ICH (R thalamic hemorrhage)	HTN Prior CVA CVA	UTI Dior CVA	CTACE 3	STAGE 3	STAGE 3
ΔΩ	78.7 4F	5 5	80	20 2	5 5	4 0	3 5	0 1	2	70	0/3	82	82	70	:) (200	0 1	0 2	8 5	200	00 0	200	80 8	72	99	200	26	22	47	55	200	32	72	67	5 6	5 8	t c	3 2	10	67
- Popular	2012	2	∟ ≤		2	2	2 ا	L 2	≅ :	Σ:	∑ :	Σ.	ا	ᆈ	L I	ㄴ :	≥ :	≥ 2	≥ 2	≥ L	ᅩ	_ 2	∑ L	L	_ 4	- ≥	2	<u> </u>	- 2	2	2	Ξ	Z	Σ	Ξļu	- 2	2	Σ	2	≦ ⊔	ᄕ
# 0000		20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 06	SJ CON 09	1WH-002	1WH -009	SU CON OZ	SJ CON 10	SJ CON 14	SJ CON 17	CO-03	71-17	01-10	01-12	200	00-10	01-10	200	07-00	CU-30	00-33	200.00	00-00	00-00	20-00	67-00	23604 - KKB	22703 - MMS

FINDER OF STATES APPENDIX A

Sequence	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(K)	(S)SKI HKIHWESASLL(K)	(S)SKITHRIHWESASLL(K)	(S)SKII HKIHWESASLL(K)	(a) JONE INCIDIO	(S)SKII HKIHWESASLL(K)	(a) JONITHAN EGAGLE(N)								·	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(K)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)												
Protein Name	Complement C3f	Complement C3t	Complement C3f	Complement C3f	Complement C3f	Complement C31	Complement C3f	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f														
MM	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1845	1845	1845	1845	1845	1845	1845	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	
Dispase	Discuss	150	불	CHF	분	SF	분	HS	长	光	SH.	CFF	CHF	C퓨	냜	불	놠	분	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	M	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	W	W	
, motor I to the	Pallelli Misioliy	STAGE 4	STAGE 3	STAGES - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3		Aphasia, Rt hemiparalysis,		The state of the s	- Control of the Cont		The state of the s		A STOCK TO THE REAL PROPERTY OF THE PROPERTY O			L CY .	Hx of prostate CA, hemodialysis		Complete hemianopia, smoker	Stroke, PM Hx, NIDDM, incr BP	A STATE OF THE STA	MODIN	MIDDIM							
	ĽL	12) /	00	27	0 0	6	3 5	45	20	99	51	64	59	92	51	62	70	84	9/								82	77	77	80	84	76	63	62	73	65	65	20	The state of the s
	ĕ	LL	ı L	L 2	2	2	2	Z	2 2	2	E L	Σ	Σ	Σ	ш	Σ	Σ	Σ	Σ	Σ								Σ	ட	. L	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ļμ	
		20206 - MM	22103 - GM	21813 - GR	23400 - GFB	20402 - FIN	20802 HB	75003 - ND	20803 - 50K	23424 - FR	22421 - LD	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	TWH-002	1WH -009	TWH-002	100- HWT	TWH-024	TWH-039	743-450	184-988	734-989	S.I.CON 01	S.I.CON 06	SJ CON 06	SJ CON 09	TWH-002	1WH -009	TWH-024	TWH-039	184-988	734-989	SI CON 07	S. CON 10	

Sequence	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(K)	(+)SSKIIHKIHWESASLL(K)	(+)SSKII HKIHWESASLL(K)	(+)SSKITHRIHWESASLL(K)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(K)													
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f						
MΜ	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865
Disease	M	M		M	M	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Ottoko-1011	Official DH	Stroke ICH	Ottoke-IOH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	CH	岩	出	CHF	SFF	出	뚱	상	CHE	CHF	CHF	出り	붕	岩	上	于C	岩	岩	당	CH
Patient History						IOI Company to MAN	ICH, secondary to Avivi		Acute CVA, basal garigina	HIN, ICH right trialinic	HIN, acute CVA		HTN, previous CVA, CVA (R MCA) used the	CVA, transier to VA	LDI NHILL	Deior CVA acrite CVA /I MCA)	HTM Soute CVA (B subcortical	HTM, Scute OVA (IN Subschilder)	HIN, Diabetes, acute CVA (1) parietal)	HIN, FIIO CVA, ICIT (N tilgianis remains activities)	HTN Prior CVA ICH	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	S HONES	S TOUCH STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3
ΔΩΦ		70	င္ပ			8	69	44	50	90	20	9/	7.5	4/	6	200	7/	7 12	70	5 5	5 5	3 2	2 6	67	75	12	65	67	67	79	9	43	45	200	8	3 2	2 6	† G	76	5 5	62
Conder	2000	≥ 2	Σ				L	-	_	Σ	Σ	ц. <u> </u>	∑ :	Σ :	≥ :	2	Σ	≦ L	L 2	≥ 2	ž	2	<u>≥</u> ⊔	ᅵᄖ	_ ⊔	_ 4	- u	. ≥	Σ	Σ	Σ	Σ	2	2	ĔΨ	- 2	2 2	2	≦ ⊔	- ≥	Σ
# 0000	7	81 NO. 18	SJ CON 21	HNS-SJZZ	HNS-SJZ8	HNS-SJ33	69-NO	CU-12	CU-15	CN-10	CU-14	CN-16	CU-18	CU-19	CU-28	CC-30	CU-33	75-00	CC-38	00-00	20-00	CU-75	23004 - NND	23707 - KL	227 U3 - MINIS	20200 - MINI	24 103 - GIM	23008 - GFR	23402 - HM	20208 - HIF	22803 - HR	22500 III	20803 EW	20000 EV	2342 - 1 D	22013 CL	23130 - EN	23105 - FC	20444 EVE	20414 - ETG	23134 - FC

FULLE TO APPENDIX A

Sequence	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKI HKIHWESASLL(K)	(+)SSKIIHKIHWESASLL(K)	(+)SSKITHRIHWESASLL(R)	(R)NGFKSHALQLNNRQIR(G)	(R)NGFKSHALQLNNRQIR(G)	(R)NGFKSHALQLNNRQIR(G)	(+)SSKITHRIHWESASLL(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)							
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C4A	Complement C4A	Complement C4A	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f								
MW	1865	1865	1865	1865	1865	1865	1865	1896	1896	1896	1998	1998	1998	1998	1998	1998	1998	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	
Disease	CHF	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	M	M	Z	Type II Diabetes	Tyne II Diahetes	W	Type II Diabetes	M	W	W	M	W	W	W	I	M	410	HZ.	HZ.	SFS	CHF														
Patient History	STAGE 3	2105.0	Complete hemianopia, smoker	Stroke, PM Hx, NIDDM, incr BP		MODIN	MIDDIM					on v						And the state of t			April 1997									A STATE OF THE STA		A CONTRACTOR OF THE PARTY OF TH		and the state of t			STATE 2	STACES	STACES	STAGE 3	STAGE 3	
000	200	2		63		73	922	2 2	28	3		+						Co	70	11		00	0 0	0/	3 6	73	2 K	3 4	00	3 3	3 2	9 6	70	00			2	0 0	00	/0	2/2	
ropado	201100	Σ		Σ		 S	2	Ξ	2 2	1								M	ΣL	L	_ 2	2	2 2	≥ 2	2	2 2	Σ	2	≥ L	נו	L	Σ	2	Σ			3	ا ≥	L .	L	L LL	-
# 2000	ç	Z010Z - EAB	700-UVI	TWH-024	TWH-039	184-988	734-080	70 NOO 1 9	S CON O		HNS-8322	1 VVII 000	TWH-024	TVVII-024	743 450	140-450	104-900	7.04-909	20 CON 01	90 CON 00	00 NOO 100	SO CON OS	200-HAA1	1 WH -009	1 WH-U24	1 WH-U39	724 080	7.04-909	SJ CON U/	92 CON 10	90 CON 14	SUCON 1	SI CON IS	SJ CON ZI	HNS-8022	HNS-SJ28	HNS-8333	23604 - KKB	23/0/ - KL	22/03 - MMS	20206 - MIM 22103 - GM	46.100 0

Sequence	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLK(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLK(-)	(+)SSKITHRIHWESASLLK(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLK(-)	(+)SSKITHRIHWESASLLK(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	SSKITHRIHWESASLLR	SSKITHRIHWESASLLK	SSKITHRIHWESASLLK	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR							
Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f																
MW	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2021	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056	2056
Disease	CHE	出	상	CHF	CHE	CHF	CHF	당	CHF	CH	CHF	出	岩	长	놠	岩	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	CHF	CHF	CHF	CHF	CHF	상	CAF	분	CFF	出	长	出	出い	岩	出り	出	岩	CHF	CHF
Patient History	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	The special section of the section o				The state of the s		STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3	STAGE 3	STAGE 3						
ΔΩΘ	28.2	24	67	62	09	43	45	59	99	21	64	29	92	51	62	02							61	65	29	75	11	65	29	29	79	09	43	45	59	99	2,1	64	200	76	21
Andono			T	†	+		+				+												Σ	E L		. LL	. ц	LL	Σ	Σ	>	Σ	2	Σ	2	ш	- 2	2 2	2	Щ	Σ
# 0000	٥	23008 CEB	23000 - GLD	20702 20208 - HIF	22803 - HB	23616 - IGK	20803 - FW	23421 - FR	22421 - CI	23130 - FR	23105 - FC	23116 - FC	20414 - FYG	23130 - FR	23134 - FC	20102 - FAR	TWH-002	TWH-009	TWH-024	TWH-039	184-988	734-989	23604 - KKR	23707 - KI	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - IGK	20803 - FW	23421 - FR	22813 - CI	22013 - CE	23100 - LIV	23116 - EC	20414 - FYG	23130 - ER

Code # Gender Age	nder	Age	Patient History	Disease MW	Protein Name	anianhac
	Σ	5	STAGE 3	CHF 2056	Complement C3f	SSKITHRIHWESASLLR
	2 2	3 5	STAGE 3	CHF 2056	Complement C3f	SSKITHRIHWESASLLR
	2 2	2 0	Insulin Resistance	Insulin Resistance 2267	Apoliprotein E	(A)TVGSLAGQPLQERAQAWGEKL(R)
	<u>≥</u> ⊔	- 0	Insulin Resistance	Insulin Resistance 2267	Apoliprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
1		- 6	Insulin Resistance	Insulin Resistance 2267	Apoliprotein E	(A)TVGSLAGQPLQERAQAWGERL(R)
-	L 2		Insulin Resistance	Insulin Resistance 2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
	Σ	- 0	Insulin Resistance	Insulin Resistance 2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
	<u>≥</u> ⊔	C	Insulin Resistance	Insulin Resistance 2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
1	_ lu	٠ ر	Insulin Resistance	Insulin Resistance 2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
	_ 1		Insulin Resistance	Insulin Resistance 2753	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVL(I)
1	- ≥	٠٠	Insulin Resistance	Insulin Resistance 2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
+	2		Insulin Resistance	Insulin Resistance 2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
_	2 L		Insulin Resistance	Insulin Resistance 2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
-	_ _ _	٠ ،	Insulin Resistance	Insulin Resistance 2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)
_		~	Insulin Resistance	Insulin Resistance 2937	Serum Albumin	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)